EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

Miriam C Aziz iD, Jennie Wilson, Clement Y Chow iD

PLOS Genetics · 2026

DOI: 10.1371/journal.pgen.1012294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, 2026. Verfasst von Miriam C Aziz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Dopamine, Drug Repositioning, Congenital Disorders of Glycosylation. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PIGA-CDG is a congenital disorder of glycosylation caused by pathogenic partial loss-of-function variants in the PIGA gene. PIGA encodes an enzyme responsible for the catalytic transfer of N-acetylglucosamine to phosphatidylinositol during the first step of glycosylphosphatidylinositol anchor biosynthesis. Loss of this enzyme has a widespread phenotypic impact, but primarily results in neurological symptoms including seizures, intellectual disability, and developmental delay. Currently, treatments are limited and focus on symptom management. We developed an eye model of PIGA-CDG that has a reduced eye size. We screened a library of 98% 1,520 FDA/EMA-approved compounds to find drugs that improved the small eye phenotype. This screen revealed numerous drugs that improved eye size, including those that targeted dopamine signaling and cyclooxygenases. Using pharmacological and genetic approaches, we show that modulating dopamine signaling improves the eye size. Genetic inhibition of dopamine 2 receptor signaling and dopamine reuptake improve both the eye model and neurologically relevant PIGA-CDG phenotypes, including seizures and locomotor deficits. We also pharmacologically and genetically validate cyclooxygenase targeting drugs in the eye model. These findings reveal novel biology underlying PIGA-CDG and point towards candidate therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DopamineDrug RepositioningCongenital Disorders of GlycosylationAnimalsSignal TransductionHumansDisease Models, AnimalEye

Substanzen

Dopamine

Autor:innen und Institutionen

  • Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.

ORCID-Profile: Miriam C Aziz, Clement Y Chow

Förderung

  • NINDS NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Aziz, M. C., Wilson, J., & Chow, C. Y. (2026). A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1012294

Vancouver

Aziz MC, Wilson J, Chow CY. A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. PLOS Genetics. 2026. doi:10.1371/journal.pgen.1012294

BibTeX
@article{Aziz2026,
  author = {Aziz, Miriam C and Wilson, Jennie and Chow, Clement Y},
  title = {A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG},
  journal = {PLOS Genetics},
  year = {2026},
  doi = {10.1371/journal.pgen.1012294}
}
Kostenlos starten →